Holen Sie sich die Stockscreener-App
18.55
2.62%
-0.50
Schlusskurs vom Vortag:
$19.05
Offen:
$18.79
24-Stunden-Volumen:
2.72M
Relative Volume:
1.01
Marktkapitalisierung:
$3.59B
Einnahmen:
$1.14B
Nettoeinkommen (Verlust:
$-250.98M
KGV:
-13.64
EPS:
-1.36
Netto-Cashflow:
$-251.61M
1W Leistung:
-16.52%
1M Leistung:
-35.77%
6M Leistung:
+6.00%
1J Leistung:
-52.52%
1-Tages-Spanne:
$18.33
$19.00
1-Wochen-Bereich:
$18.33
$20.80
52-Wochen-Spanne:
$16.24
$39.27
Legend Biotech Corp Adr Stock (LEGN) Company Profile
Firmenname
Legend Biotech Corp Adr
Sektor
Branche
Telefon
-
Adresse
-
Compare LEGN vs VRTX, REGN, ARGX, RVMD, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
LEGN
Legend Biotech Corp Adr
|
18.55 | 3.73B | 1.14B | -250.98M | -251.61M | -1.36 |
VRTX
Vertex Pharmaceuticals Inc
|
477.10 | 121.57B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
762.63 | 69.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
853.82 | 55.61B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
187.53 | 39.98B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
316.01 | 33.81B | 5.76B | 514.49M | 1.10B | 4.4813 |
Legend Biotech Corp Adr Stock (LEGN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-12 | Herabstufung | Rothschild & Co Redburn | Buy → Neutral |
| 2026-01-22 | Herabstufung | TD Cowen | Buy → Hold |
| 2026-01-07 | Eingeleitet | Oppenheimer | Outperform |
| 2025-10-07 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-10-08 | Eingeleitet | Redburn Atlantic | Buy |
| 2024-06-17 | Eingeleitet | Truist | Buy |
| 2024-05-24 | Bestätigt | H.C. Wainwright | Buy |
| 2024-05-23 | Eingeleitet | Deutsche Bank | Buy |
| 2024-04-17 | Hochstufung | Scotiabank | Sector Perform → Sector Outperform |
| 2024-04-03 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-03-13 | Eingeleitet | Raymond James | Outperform |
| 2023-12-19 | Eingeleitet | Scotiabank | Sector Perform |
| 2023-11-06 | Eingeleitet | Goldman | Buy |
| 2023-05-25 | Eingeleitet | William Blair | Mkt Perform |
| 2023-05-22 | Eingeleitet | Daiwa Securities | Buy |
| 2023-03-29 | Eingeleitet | H.C. Wainwright | Buy |
| 2023-03-24 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2022-12-06 | Eingeleitet | UBS | Buy |
| 2022-11-02 | Eingeleitet | Evercore ISI | Outperform |
| 2022-11-01 | Eingeleitet | Cowen | Outperform |
| 2022-10-31 | Eingeleitet | Guggenheim | Neutral |
| 2022-06-17 | Eingeleitet | BMO Capital Markets | Outperform |
| 2022-03-15 | Eingeleitet | Barclays | Overweight |
| 2022-01-31 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2022-01-06 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-12-21 | Eingeleitet | Piper Sandler | Overweight |
| 2021-05-18 | Eingeleitet | BTIG Research | Buy |
| 2020-07-01 | Eingeleitet | JP Morgan | Overweight |
| 2020-07-01 | Eingeleitet | Jefferies | Buy |
| 2020-06-30 | Eingeleitet | Morgan Stanley | Overweight |
Alle ansehen
Legend Biotech Corp Adr Aktie (LEGN) Neueste Nachrichten
H.C. Wainwright reiterates Buy on Legend Biotech stock, $65 target - Investing.com
Raymond James cuts Legend Biotech stock price target on CEO departure - Investing.com
Why is Legend Biotech stock sliding today? By Investing.com - Investing.com South Africa
Why is Legend Biotech stock sliding today? - Investing.com
Legend Biotech stock falls as CEO Ying Huang steps down By Investing.com - Investing.com South Africa
Legend Biotech stock falls as CEO Ying Huang steps down - Investing.com
Legend Biotech CEO Ying Huang steps down, Alan Bash named interim By Investing.com - Investing.com South Africa
Legend Biotech CEO Ying Huang steps down, Alan Bash named interim - Investing.com
UBS downgrades Legend Biotech stock rating on competition concerns - Investing.com
UBS downgrades Legend Biotech stock rating on competition concerns By Investing.com - Investing.com India
Analysts Offer Insights on Healthcare Companies: Medicinova (MNOV), Legend Biotech (LEGN) and AngioDynamics (ANGO) - The Globe and Mail
H.C. Wainwright reiterates Legend Biotech stock rating on strong Carvykti sales - Investing.com
JPMorgan resumes Legend Biotech stock coverage with neutral rating By Investing.com - Investing.com South Africa
JPMorgan resumes Legend Biotech stock coverage with neutral rating - Investing.com
Legend Biotech (LEGN) Short Interest & Short Float | Updated Jul 2026 - MarketBeat
LEGNLegend Biotech Corp ADR Options - Finviz
Legend Biotech (LEGN) CEO Ying Huang makes charitable gift of 3,382 shares - Stock Titan
Form 144 Legend Biotech Corp For: 30 June By Investing.com - Investing.com India
Form 4 Legend Biotech Corp For: 29 June - Investing.com India
Legend Biotech CEO Huang Ying sells $82,265 in shares By Investing.com - Investing.com South Africa
Form 4 Legend Biotech Corp For: 29 June By Investing.com - Investing.com South Africa
Legend Biotech CEO Huang Ying sells $82,265 in shares - Investing.com
Form 144 Legend Biotech Corp For: 26 June By Investing.com - Investing.com South Africa
Legend Biotech (LEGN) 10K Form and Latest SEC Filings 2026 - MarketBeat
Legend Biotech Corp. Sponsored ADR Actuals & Estimates (NASDAQ:LEGN) - TradingView
9LB Forecast — Price Target — Prediction for 2027 - TradingView
After Apogee, 3 More Biotech Buyout Targets Wall Street Can’t Stop Watching - AOL.com
Form 6K Legend Biotech Corp For: 22 June By Investing.com - Investing.com South Africa
Form 424B5 Legend Biotech Corp - StreetInsider
Legend Biotech (LEGN) raises ~$211.6M selling 7.7M ADSs; option for 1.155M more - Stock Titan
symbol__ Stock Quote Price and Forecast - CNN
Why Is Legend Biotech Stock Falling Thursday? - Benzinga
Legend Biotech prices $226 million public offering at $29.35 By Investing.com - Investing.com South Africa
Legend Biotech prices $226 million public offering at $29.35 - Investing.com
Legend Biotech launches $225 million public share offering - Investing.com
Legend Biotech stock falls on $225M share offering plan - Investing.com
Legend Biotech (NASDAQ: LEGN) files $225M ADS offering to fund pipeline - Stock Titan
Legend Biotech stock falls on $225M share offering plan By Investing.com - Investing.com India
Legend Biotech reports early trial success for in vivo CAR-T therapy - Investing.com
Legend Biotech reports early trial success for in vivo CAR-T therapy By Investing.com - Investing.com South Africa
UBS raises Legend Biotech stock price target on NHL therapy outlook By Investing.com - Investing.com South Africa
UBS raises Legend Biotech stock price target on NHL therapy outlook - Investing.com
GENSCRIPT BIO Spikes 19% as Legend Biotech Corporation (LEGN.US) Announces Positive Prelim Clinical Data for Lymphoma Therapy - aastocks.com
Cancer Drug Proves 100% Successful In Early Study; What's Next? - Investor's Business Daily
Keep an eye on the top gainers and losers in Tuesday's session. - ChartMill
Legend Biotech reports phase 1 data for in vivo CAR-T therapy - Investing.com
RBC Capital reiterates Legend Biotech stock rating at Outperform By Investing.com - Investing.com South Africa
RBC Capital reiterates Legend Biotech stock rating at Outperform - Investing.com
H.C. Wainwright reiterates Legend Biotech stock rating at buy - Investing.com
Legend Biotech Conference Spotlights CARVYKTI’s Curative Potential, Earlier Use - Yahoo Finance
H.C. Wainwright reiterates Legend Biotech stock rating at buy By Investing.com - Investing.com South Africa
Finanzdaten der Legend Biotech Corp Adr-Aktie (LEGN)
Umsatz
Nettogewinn
Free Cashflow
ENV
Legend Biotech Corp Adr-Aktie (LEGN) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Huang Ying | Chief Executive Officer |
Jun 25 '26 |
Sale |
14.78 |
5,566 |
82,265 |
241,872 |
2.44%
0.02%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):